Therapeutic Targeting of Telomerase
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Telomere length and cell function can be preserved by the human reverse transcriptase telomerase (hTERT), which synthesizes the new telomeric DNA from a RNA template, but is normally restricted to cells needing a high proliferative capacity, such as stem cells. Consequently, telomerase-based therapies to elongate short telomeres are developed, some of which have successfully reached the stage I in clinical trials. Telomerase is also permissive for tumorigenesis and 90% of all malignant tumors use telomerase to obtain immortality. Thus, reversal of telomerase upregulation in tumor cells is a potential strategy to treat cancer. Natural and small-molecule telomerase inhibitors, immunotherapeutic approaches, oligonucleotide inhibitors, and telomerase-directed gene therapy are useful treatment strategies. Telomerase is more widely expressed than any other tumor marker. The low expression in normal tissues, together with the longer telomeres in normal stem cells versus cancer cells, provides some degree of specificity with low risk of toxicity. However, long term telomerase inhibition may elicit negative effects in highly-proliferative cells which need telomerase for survival, and it may interfere with telomere-independent physiological functions. Moreover, only a few hTERT molecules are required to overcome senescence in cancer cells, and telomerase inhibition requires proliferating cells over a sufficient number of population doublings to induce tumor suppressive senescence. These limitations may explain the moderate success rates in many clinical studies. Despite extensive studies, only one vaccine and one telomerase antagonist are routinely used in clinical work. For complete eradication of all subpopulations of cancer cells a simultaneous targeting of several mechanisms will likely be needed. Possible technical improvements have been proposed including the development of more specific inhibitors, methods to increase the efficacy of vaccination methods, and personalized approaches. Telomerase activation and cell rejuvenation is successfully used in regenerative medicine for tissue engineering and reconstructive surgery. However, there are also a number of pitfalls in the treatment with telomerase activating procedures for the whole organism and for longer periods of time. Extended cell lifespan may accumulate rare genetic and epigenetic aberrations that can contribute to malignant transformation. Therefore, novel vector systems have been developed for a ‘mild’ integration of telomerase into the host genome and loss of the vector in rapidly-proliferating cells. It is currently unclear if this technique can also be used in human beings to treat chronic diseases, such as atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific Association of Human Telomerase Activity with Immortal Cells and Cancer
Kim, N. W., Piatyszek, M. A., Prowse, K. R., Harley, C. B., West, M. D., Ho, P. L. C., Coviello, G. M., Wright, W. E., Weinrich, S. L., & Shay, J. W. (1994) · Science · doi:10.1126/science.7605428 · Cited by 7,091 · cited 2×
“First, it is an essential and specific component for most cancer cells [129,138] and more widely expressed than any other tumor marker.”
BackgroundExtension of Life-Span by Introduction of Telomerase into Normal Human Cells
Bodnar, A. G., Ouellette, M., Frolkis, M., Holt, S. E., Chiu, C.-P., Morin, G. B., Harley, C. B., Shay, J. W., Lichtsteiner, S., & Wright, W. E. (1998) · Science · doi:10.1126/science.279.5349.349 · Cited by 4,975
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Shelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“, when telomeres shorten beyond a critical threshold, unprotected telomeres provoke a DNA damage response [7].”
Oxidative stress shortens telomeres
von Zglinicki, T. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02110-2 · Cited by 2,524 · cited 2×
“The variety in telomere length in individuals of the same age is determined by genetic and envir nmental fa tors, leading to telom re damage and accelerated shortening of telomere length [14,15].”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“Antisense oligonucleotides and chemically-modified nucleic acids have been shown to inhibit telomerase and to induce telomere shortening [131–135] associated with subsequent onset of senescence and/or apoptosis in cell cultures [134–137].”
BackgroundCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 1×
“On one hand, both telomere-driven replicative senescence and stress-inducible senescence are tumor-suppressive [241–247].”
BackgroundTERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 1×
“The recent finding of a germline mutation in the promoter of hTERT in a melanoma-prone family further suggests the importance of telomerase as an important target in skin cancer therapy [236].”
BackgroundOncogene-induced senescence as an initial barrier in lymphoma development
Braig, M., Lee, S., Loddenkemper, C., Rudolph, C., Peters, A. H. F. M., Schlegelberger, B., Stein, H., Dörken, B., Jenuwein, T., & Schmitt, C. A. (2005) · Nature · doi:10.1038/nature03841 · Cited by 1,220
Aubert, G., & Lansdorp, P. M. (2008) · Physiological Reviews · doi:10.1152/physrev.00026.2007 · Cited by 1,188
Vaziri, H., & Benchimol, S. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70109-5 · Cited by 1,003
Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979
Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice
Jaskelioff, M., Muller, F. L., Paik, J.-H., Thomas, E., Jiang, S., Adams, A. C., Sahin, E., Kost-Alimova, M., Protopopov, A., Cadiñanos, J., et al. (2011) · Nature · doi:10.1038/nature09603 · Cited by 857 · cited 2×
“These pathways are functionally-relevant downstream drug effects and are also activation pathways for telomerase, suggesting a potential (yet unproven) mechanism by which these drugs may mediate neurogenesis via telomerae activation [38,128].”
BackgroundTherapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · cited 1×
“On one hand, both telomere-driven replicative senescence and stress-inducible senescence are tumor-suppressive [241–247].”
BackgroundTelomeres and telomerase in cancer
Artandi, S. E., & DePinho, R. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp268 · Cited by 823 · cited 1×
“Telomere shortening occurs due to the so-called end replication problem, which means that the 3’ end of the DNA strand shortens with each cell division, since the DNA polymerase cannot completely replicate the strand [5,8].”
BackgroundMitochondrial dysfunction accounts for the stochastic heterogeneity in telomere-dependent senescence
Passos, J. F., Saretzki, G., Ahmed, S., Nelson, G., Richter, T., Peters, H., Wappler, I., Birket, M. J., Harold, G., Schaeuble, K., et al. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050110 · Cited by 796 · cited 1×
“The idea behind this concept is that ROS damage telomeres directly (by damaging the vulnerable GGG triplet of the repetitive telomere sequence) and indirectly (by modulating telomerase activity and cellular location) [101].”
BackgroundLinking functional decline of telomeres, mitochondria and stem cells during ageing
Sahin, E., & DePinho, R. A. (2010) · Nature · doi:10.1038/nature08982 · Cited by 759 · cited 1×
“Replicative senescence contributes to the decline in many physiological functions and in most tissues and, thus, contributes to the pathology of chronic diseases [35,36].”
BackgroundTelomerase and cancer therapeutics
Harley, C. B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2275 · Cited by 728
Telomerase modulates Wnt signalling by association with target gene chromatin
Park, J.-I., Venteicher, A. S., Hong, J. Y., Choi, J., Jun, S., Shkreli, M., Chang, W., Meng, Z., Cheung, P., Ji, H., et al. (2009) · Nature · doi:10.1038/nature08137 · Cited by 707 · cited 1×
“, as a cofactor in a β-catenin transcriptional complex [12], which plays a role in embryogenesis and development [13].”
BackgroundBernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200245 · Cited by 548
Herbert, B.-S., Pitts, A. E., Baker, S. I., Hamilton, S. E., Wright, W. E., Shay, J. W., & Corey, D. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14276 · Cited by 539 · cited 1×
“Antisense oligonucleotides and chemically-modified nucleic acids have been shown to inhibit telomerase and to induce telomere shortening [131–135] associated with subsequent onset of senescence and/or apoptosis in cell cultures [134–137].”
BackgroundTelomere dysfunction and evolution of intestinal carcinoma in mice and humans
Rudolph, K. L., Millard, M., Bosenberg, M. W., & DePinho, R. A. (2001) · Nature Genetics · doi:10.1038/88871 · Cited by 527 · cited 1×
“By induction of telomere dysfunction and attrition chromosomal instability occurs and may result in activation of oncogenes and/or silencing of tumor suppressor genes, which may counteract the original therapeutic intention and cooperate to promote malignant transformation and drug resistance [248–252].”
BackgroundDNA repair is limiting for haematopoietic stem cells during ageing
Nijnik, A., Woodbine, L., Marchetti, C., Dawson, S., Lambe, T., Liu, C., Rodrigues, N. P., Crockford, T. L., Cabuy, E., Vindigni, A., et al. (2007) · Nature · doi:10.1038/nature05875 · Cited by 518
Telomerase Reverse Transcriptase Delays Aging in Cancer-Resistant Mice
Tomás-Loba, A., Flores, I., Fernández-Marcos, P. J., Cayuela, M. L., Maraver, A., Tejera, A., Borrás, C., Matheu, A., Klatt, P., Flores, J. M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.034 · Cited by 484 · cited 1×
“In mice with cancer resistant backgrounds (by increased expression of tumor suppressors p16, Arf, and p53) transgenic telomerase expression extends lifespan by 43% [254].”
BackgroundConditional telomerase induction causes proliferation of hair follicle stem cells
Sarin, K. Y., Cheung, P., Gilison, D., Lee, E., Tennen, R. I., Wang, E., Artandi, M. K., Oro, A. E., & Artandi, S. E. (2005) · Nature · doi:10.1038/nature03836 · Cited by 425
A highly selective telomerase inhibitor limiting human cancer cell proliferation
Damm, K., Hemmann, U., Garin‐Chesa, P., Hauel, N., Kauffmann, I., Priepke, H., Niestroj, C., Daiber, C., Enenkel, B., Guilliard, B., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6958 · Cited by 422
The power and the promise of oncogene-induced senescence markers
Collado, M., & Serrano, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1884 · Cited by 404
Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359 · cited 1×
“At least 23 clinical studies, summarized in [151] have investigated hTERT immunotherapy as anticancer strategy in melanoma, acute myeloid leukemia, glioblastoma, prostate, renal, pancreatic, hepatocellular, and non-small-cell lung cancer: 18 phase I/I-II studies [152–168], four phase II studies [169–172], and one phas…”
Backgroundde Jesus, B. B., Schneeberger, K., Vera, E., Tejera, A., Harley, C. B., & Blasco, M. A. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00700.x · Cited by 348
Chromosomal instability in ulcerative colitis is related to telomere shortening
O'Sullivan, J. N., Bronner, M. P., Brentnall, T. A., Finley, J. C., Shen, W.-T., Emerson, S., Emond, M. J., Gollahon, K. A., Moskovitz, A. H., Crispin, D. A., et al. (2002) · Nature Genetics · doi:10.1038/ng989 · Cited by 346
Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts
Wyllie, F. S., Jones, C. J., Skinner, J. W., Haughton, M. F., Wallis, C., Wynford-Thomas, D., Faragher, R. G. A., & Kipling, D. (2000) · Nature Genetics · doi:10.1038/71630 · Cited by 332
Oh, H., Taffet, G. E., Youker, K. A., Entman, M. L., Overbeek, P. A., Michael, L. H., & Schneider, M. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191169098 · Cited by 289
Davoli, T., & de Lange, T. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.044 · Cited by 242 · cited 1×
“At least 23 clinical studies, summarized in [151] have investigated hTERT immunotherapy as anticancer strategy in melanoma, acute myeloid leukemia, glioblastoma, prostate, renal, pancreatic, hepatocellular, and non-small-cell lung cancer: 18 phase I/I-II studies [152–168], four phase II studies [169–172], and one phas…”
BackgroundSignificant Role for p16INK4a in p53-Independent Telomere-Directed Senescence
Jacobs, J. J. L., & de Lange, T. (2004) · Current Biology · doi:10.1016/j.cub.2004.12.025 · Cited by 237 · cited 2×
“The p16/pRb tumor suppressor pathways are activated in response to DNA damage and telomere dysfunction during senescence [23–25].”
BackgroundChang, S., Khoo, C. M., Naylor, M. L., Maser, R. S., & DePinho, R. A. (2003) · Genes & Development · doi:10.1101/gad.1029903 · Cited by 183
Long-term lithium treatment in bipolar disorder is associated with longer leukocyte telomeres
Martinsson, L., Wei, Y., Xu, D., Melas, P. A., Mathé, A. A., Schalling, M., Lavebratt, C., & Backlund, L. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.37 · Cited by 179 · cited 1×
“In patients with bipolar disorder, telomere length correlated with duration of therapy [125].”
BackgroundTransformation of normal human cells in the absence of telomerase activation
Seger, Y. R., Garcı́a-Cao, M., Piccinin, S., Cunsolo, C. L., Doglioni, C., Blasco, M. A., Hannon, G. J., & Maestro, R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00183-6 · Cited by 159
Inhibition of human telomerase by 2′- O -methyl-RNA
Pitts, A. E., & Corey, D. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11549 · Cited by 144
Dyskeratosis Congenita - A Disease of Dysfunctional Telomere Maintenance
Mason, P., Wilson, D., & Bessler, M. (2005) · Current Molecular Medicine · doi:10.2174/1566524053586581 · Cited by 129
Bär, C., Povedano, J. M., Serrano, R., Benitez-Buelga, C., Popkes, M., Formentini, I., Bobadilla, M., Bosch, F., & Blasco, M. A. (2016) · Blood · doi:10.1182/blood-2015-08-667485 · Cited by 116 · cited 1×
“Transient telomerase activation may also be used for the treatment of other chronic diseases such as cardiac muscle disease, atherosclerosis [15], immunodeficiency, and bone marrow failure [11,80], liver disease [11,81], pulmonary fibrosis [11,82], degenerative cartilage defects [83], cataract [84], rheumatoid arthrit…”
BackgroundRejuvenating the immune system in rheumatoid arthritis.
Weyand, C. M., Fujii, H., Shao, L., & Goronzy, J. J. (2009) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.180 · Cited by 112 · cited 1×
“Transient telomerase activation may also be used for the treatment of other chronic diseases such as cardiac muscle disease, atherosclerosis [15], immunodeficiency, and bone marrow failure [11,80], liver disease [11,81], pulmonary fibrosis [11,82], degenerative cartilage defects [83], cataract [84], rheumatoid arthrit…”
BackgroundAntagonistic effects of telomerase on cancer and aging in K5-mTert transgenic mice
González-Suárez, E., Geserick, C., Flores, J. M., & Blasco, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208413 · Cited by 109 · cited 1×
“Constitutive telomerase expression in mice increased tissue fitness and delay of aging at the expense of slightly increased cancer incidence [254–256].”
BackgroundHippocampal telomerase is involved in the modulation of depressive behaviors
Zhou, Q.-G., Hu, Y., Wu, D.-L., Zhu, L.-J., Chen, C., Jin, X., Luo, C.-X., Wu, H.-Y., Zhang, J., & Zhu, D.-Y. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0805-11.2011 · Cited by 105 · cited 2×
“Fluoxetine reversed clinical symptoms and increased hippocampal telomerase activity in parallel, raising the possibility that drug effects might be mediated by telomerase-dependent neurogenesis [121].”
BackgroundSiegl-Cachedenier, I., Flores, I., Klatt, P., & Blasco, M. A. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200704141 · Cited by 64
Dow, C. T., & Harley, C. (2016) · Clinical Ophthalmology · doi:10.2147/opth.s100042 · Cited by 56
Zhang, X., Li, B., de Jonge, N., Björkholm, M., & Xu, D. (2015) · Oncotarget · doi:10.18632/oncotarget.2917 · Cited by 38
Nucleotide excision repair and related human diseases
Bergoglio, V., & Magnaldo, T. (2006) · Genome Dynamics · doi:10.1159/000092499 · Cited by 25 · cited 1×
“[224–234].”
Cited by
TERT—Regulation and Roles in Cancer Formation
Dratwa, M., Wysoczańska, B., Łacina, P., Kubik, T., & Bogunia-Kubik, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589929 · Cited by 311
Telomeres and Telomere Length: A General Overview
Srinivas, N., Rachakonda, S., & Kumar, R. (2020) · Cancers · doi:10.3390/cancers12030558 · Cited by 304
The Link between Chronic Stress and Accelerated Aging
Yegorov, Y. E., Poznyak, A. V., Nikiforov, N. G., Sobenin, I. A., & Orekhov, A. N. (2020) · Biomedicines · doi:10.3390/biomedicines8070198 · Cited by 147
Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
Frey, N., Venturelli, S., Zender, L., & Bitzer, M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.146 · Cited by 97
Natural products with anti-aging potential: Affected targets and molecular mechanisms
Cătană, C.-S., Atanasov, A. G., & Berindan-Neagoe, I. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.03.012 · Cited by 92
Metadata
- Authors
- Jäger, K., & Walter, M.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2016-07-21
- Volume
- 7
- Issue
- 7
- Pages
- 39
- ISSN
- 2073-4425 (ISSN-L)
- OpenAlex
- W2490200714
- Cited by
- 139
- References
- 50
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.